Elektrofi Inc., a biopharmaceutical delivery technology company, has closed an upsized $112.25 million Series C financing. The round was co-led by Novo Holdings, RA Capital Management, Royalty Pharma, SR One, and TPG Life Sciences Innovations, with participation from Eli Lilly and Company and other prominent life science investors.
 
The fresh capital will be used to establish Phase 3 and commercial-scale Good Manufacturing Practice (GMP) manufacturing lines. This expansion, coupled with the company’s first GMP line slated for early 2025, aims to accelerate the development and launch of its pipeline.
 
Elektrofi’s technology platform, Hypercon, is designed to concentrate and stabilize biopharmaceuticals, enabling self-administration and potentially expanding patient access to life-saving treatments.
 
“At Elektrofi, we envision a world in which patients have the independence they need – around how and where they take their medications – to live life on their terms,” said Chase Coffman, CEO. “The industry is on the cusp of a drug delivery revolution, and Elektrofi is proud to be leading it with Hypercon, a broadly applicable platform for the hyper concentration and stabilization of biopharmaceuticals. With our team of industry experts, distinguished Board Directors, world-class investors, and pharma partners, we look forward to scaling our proprietary technology in the interest of bringing life-changing medicines to patients across the globe as quickly as possible.”